Skip to main content
. 2022 Oct 18;18(16):6129–6144. doi: 10.7150/ijbs.74951

Figure 2.

Figure 2

Silencing of BMAL1 enhanced HCC cell proliferation and metastasis. (A) MTS assay for SNU-368 and SNU-739 cells treated as specified (siBMAL1, siRNA against BMAL1; siCtrl, control siRNA). (B) Colony formation assay for SNU-368 and SNU-739 cells treated as specified. (C) Scratch-wound-healing analysis for migration abilities of SNU-368 and SNU-739 cells treated as specified. (D) Matrigel invasion assay for invasive abilities of SNU-368 and SNU-739 cells after treatments as specified. (E) Subcutaneous tumor-growth curves for HCC cells stably transfected with short-hairpin RNA targeting BMAL1 (n=6 mice/group). (F) Dissected subcutaneous tumors from sacrificed mice (left panel), with their weights (right panel) (n=6 mice/group). (G) Numbers of lung metastasis nodules in each group (n=6 mice/group). Scale bar, 100 µm. *p <0.05.